OCUGEN, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.764 EUR | +0.11% |
|
+7.50% | +220.95% |
| 07-01 | Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Small Cap Completeness Index | CI |
| 07-01 | Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Microcap Growth Index | CI |
| Sales 2024 * | 671K 614K 917K | Sales 2025 * | - | Capitalization | 502M 459M 686M |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -53.93M -80.61M | Net income 2025 * | -81M -74.04M -111M | EV / Sales 2024 * | 748 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-9
x | P/E ratio 2025 * |
-6.65
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ocugen, Inc.
More recommendations
More press releases
More news
| 1 week | +7.50% | ||
| Current month | +32.68% | ||
| 1 month | +33.38% | ||
| 3 months | +19.70% | ||
| 6 months | +244.28% | ||
| Current year | +220.95% |
1 week
1.57
1.77
1 month
1.101.77
3 years
0.3315.88
5 years
0.1616.06
| Managers | Title | Age | Since |
|---|---|---|---|
Shankar Musunuri
CEO | Chief Executive Officer | 60 | 12-12-31 |
| Director of Finance/CFO | 42 | - | |
Jesse Simmers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 22-03-16 | |
| Director/Board Member | 74 | 20-04-04 | |
Shankar Musunuri
CEO | Chief Executive Officer | 60 | 12-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 1.764 | +0.11% |
| 24-07-16 | 1.762 | +2.68% |
| 24-07-15 | 1.716 | +1.66% |
| 24-07-12 | 1.688 | +1.26% |
| 24-07-11 | 1.667 | +1.89% |
Delayed Quote Börse Stuttgart, July 17, 2024 at 05:06 am
More quotes
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Calendar
2024-08-01
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.95
USD
Average target price
6.667
USD
Spread / Average Target
+241.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 47.96B | |
| +45.94% | 41.47B | |
| +0.69% | 42.45B | |
| +30.52% | 31.6B | |
| +22.30% | 28.63B | |
| -6.35% | 28.03B | |
| +49.25% | 14.56B | |
| +49.18% | 14.14B | |
| +3.45% | 12.58B |
- Stock Market
- Equities
- OCGN Stock
- 2H51 Stock
